ARTICLE | Company News
Triphase, Celgene deal
November 3, 2014 8:00 AM UTC
Triphase granted Celgene an option to license exclusive, worldwide rights, excluding China and Korea, to develop and commercialize TRPH 011. The human bispecific antibody targeting VEGF receptor 2 ( ...